Welcome to our dedicated page for NUACF news (Ticker: $NUACF), a resource for investors and traders seeking the latest updates and insights on NUACF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NUACF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NUACF's position in the market.
Natura & Co's Q1 2024 financial results reveal a mixed performance. Consolidated net revenue hit BRL 6.1 billion, showing a 1.1% rise in constant currency but a 5.7% decline year-on-year in Brazilian Reais. Natura Latam excelled, with revenue growth of 3.1% YoY in CC, led by Natura Brazil's 11.3% increase. This was driven by strong retail sales and the launch of the 'Perfumada' fragrance campaign. However, Avon Latam reported declines of over 11% in Brazil and Hispanic Latam due to fewer representatives.
Avon International faced a 4.7% revenue drop in CC despite efforts to enhance gross margins and explore new distribution channels. Consolidated profitability improved thanks to a 90 bps increase in gross margin, reaching 65.2%. Adjusted EBITDA was BRL 683 million, with a margin expansion of 110 bps YoY.
However, the reported net loss widened to BRL 935 million, impacted by discontinued operations, higher taxes, and FX losses. Excluding one-offs, the underlying net income was BRL 116 million. CEO Fabio Barbosa highlighted the positive impact of the Natura-Avon integration but acknowledged ongoing challenges.